Momenta Phamaceuticals (MNTA) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Total operating expenses: 47.33M
Today's EPS Names:
ZVOI, SYRS, ATRA, More
Financial Fact:
Total operating expenses: 47.33M
Today's EPS Names:
ZVOI, SYRS, ATRA, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.35), $0.06 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $10.41 million. Momenta Phamaceuticals, Inc. reaffirmed FY2013 guidance.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BrightSpring Health Services, Inc. (BTSG) Tops Q3 EPS by 34c ; Offers Guidance
- FST Corp. (KBSX) Reports In-Line Q3 EPS
- WisdomTree, Inc. (WT) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
